VCYT Veracyte Inc

Morgan Stanley has initiated coverage of Veracyte, Inc. (NASDAQ: VCYT) with an Underweight rating and a price target of $48, citing increasing bright spots in the Life Science Tools and Diagnostics markets. Veracyte has also boosted its full-year 2025 guidance for total sales, testing revenue, and adjusted EBITDA margin. Although acknowledging the potential of VCYT, the article suggests that other AI stocks might offer higher returns in a shorter timeframe.

Veracyte, Inc. announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. A live audio webcast will be available on Veracyte’s website, with a replay accessible for 30 days. Veracyte is a global diagnostics company focused on transforming cancer care with high-performing tests driven by genomic and AI capabilities.

Veracyte, Inc. (Nasdaq: VCYT), a cancer diagnostics company, announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 9:45 a.m. Pacific Time. A live audio webcast and subsequent replay will be available on Veracyte's investor relations website. The company aims to transform cancer care through its Veracyte Diagnostics Platform, offering high-performing cancer tests driven by genomic data, AI capabilities, and evidence generation.

Wall Street Zen has upgraded Veracyte (NASDAQ:VCYT) to a "strong-buy" rating, with other analysts also raising price targets, contributing to a "Moderate Buy" consensus and a $45.43 target price from MarketBeat. The company recently exceeded earnings expectations, reporting an EPS of $0.51 against an anticipated $0.32, and revenue of $131.9M compared to an expected $124.6M, representing a 13.8% year-over-year increase. Despite recent insider selling, institutional investors have shown increased interest, with several hedge funds and investment firms adding to their positions in Veracyte.

Assenagon Asset Management S.A. significantly reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 96.7% in the third quarter, selling 803,061 shares. Company insiders, including Director Karin Eastham and SVP Annie McGuire, also offloaded shares totaling over $6.28 million. Despite these sales, Veracyte reported strong Q3 earnings, beating analyst estimates, and currently holds a "Moderate Buy" consensus rating with a target price of $45.43.

Veracyte's SVP Annie Mcguire sold 10,739 shares of the company's stock for $463,173.07 on December 16, decreasing her holding by 13.68%. This sale follows previous transactions by Mcguire. Veracyte recently surpassed quarterly earnings estimates, with analysts maintaining a "Moderate Buy" rating and an average price target of $45.43.